ZA201900438B - Combination therapies for treating cancer - Google Patents

Combination therapies for treating cancer

Info

Publication number
ZA201900438B
ZA201900438B ZA201900438A ZA201900438A ZA201900438B ZA 201900438 B ZA201900438 B ZA 201900438B ZA 201900438 A ZA201900438 A ZA 201900438A ZA 201900438 A ZA201900438 A ZA 201900438A ZA 201900438 B ZA201900438 B ZA 201900438B
Authority
ZA
South Africa
Prior art keywords
treating cancer
combination therapies
therapies
combination
cancer
Prior art date
Application number
ZA201900438A
Other languages
English (en)
Inventor
John H Bushweller
Anuradha Illendula
Original Assignee
Univ Virginia Patent Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Virginia Patent Foundation filed Critical Univ Virginia Patent Foundation
Publication of ZA201900438B publication Critical patent/ZA201900438B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA201900438A 2016-07-27 2019-01-22 Combination therapies for treating cancer ZA201900438B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662367263P 2016-07-27 2016-07-27
PCT/US2017/044124 WO2018022855A1 (en) 2016-07-27 2017-07-27 Combination therapies for treating cancer

Publications (1)

Publication Number Publication Date
ZA201900438B true ZA201900438B (en) 2019-10-30

Family

ID=61016782

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA201900438A ZA201900438B (en) 2016-07-27 2019-01-22 Combination therapies for treating cancer

Country Status (13)

Country Link
US (1) US11241421B2 (enExample)
EP (1) EP3490557B1 (enExample)
JP (1) JP2019525924A (enExample)
KR (1) KR20190032370A (enExample)
CN (1) CN109475542A (enExample)
AU (1) AU2017302330A1 (enExample)
BR (1) BR112019000049A2 (enExample)
CA (1) CA3028461A1 (enExample)
EA (1) EA201990395A1 (enExample)
IL (1) IL263942A (enExample)
MX (1) MX2019000179A (enExample)
WO (1) WO2018022855A1 (enExample)
ZA (1) ZA201900438B (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019226975A1 (en) * 2018-05-24 2019-11-28 University Of Virginia Patent Foundation Combination therapies for treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643935A (en) * 1995-06-07 1997-07-01 The University Of North Carolina At Chapel Hill Method of combatting infectious diseases using dicationic bis-benzimidazoles
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
WO2006104668A2 (en) 2005-03-11 2006-10-05 Temple University - Of The Commonwealth System Of Higher Education Composition and methods for the treatment of proliferative diseases
WO2007008490A2 (en) * 2005-07-06 2007-01-18 Kanisa Pharmaceuticals, Inc. Zosuquidar, daunorubicin, and cytarabine for the treatment of cancer
ES2787599T3 (es) * 2009-05-13 2020-10-16 Univ Virginia Patent Foundation Inhibidores de leucemia inv(16)

Also Published As

Publication number Publication date
US20190343820A1 (en) 2019-11-14
EP3490557B1 (en) 2022-09-07
MX2019000179A (es) 2019-06-20
IL263942A (en) 2019-02-28
KR20190032370A (ko) 2019-03-27
BR112019000049A2 (pt) 2019-04-02
US11241421B2 (en) 2022-02-08
AU2017302330A1 (en) 2019-01-17
WO2018022855A1 (en) 2018-02-01
EA201990395A1 (ru) 2019-07-31
EP3490557A4 (en) 2020-04-01
JP2019525924A (ja) 2019-09-12
CN109475542A (zh) 2019-03-15
EP3490557A1 (en) 2019-06-05
CA3028461A1 (en) 2018-02-01

Similar Documents

Publication Publication Date Title
IL270720A (en) Combination of treatments for cancer treatment
IL273395A (en) Combined therapies for cancer treatment
IL253573A0 (en) Combined therapies for the treatment of cancers
IL254705A0 (en) Combination therapy for cancer
IL255060A0 (en) Combined treatment for cancer
IL251464A0 (en) Combination therapy for cancer
SG11201708861VA (en) Methods for treating cancer
SG11201609770TA (en) Combination therapies for the treatment of cancer
EP3180010A4 (en) Combination therapy for treating cancer
IL257073A (en) Combined therapies for cancer treatment
EP3193884A4 (en) Combination therapy for treating cancer
IL256836B (en) Methods for treating cancer using apilimod
IL249898A0 (en) Combined cancer treatment
IL255022A0 (en) Cancer treatment methods
ZA201900052B (en) Pharmaceutical combinations for treating cancer
IL246761A0 (en) Combined cancer treatment
IL255018A0 (en) Cancer treatment methods
IL255016A0 (en) Cancer treatment methods
IL278921A (en) Combined treatments for cancer
ZA201900438B (en) Combination therapies for treating cancer
IL259097A (en) Combination therapy for cancer
HK40026210A (en) Combination therapies for treating cancer
HK40026532A (zh) 用於治疗癌症的组合疗法
HK40025024A (en) Combination therapies for treating cancer
HK1240117A1 (en) Combination therapies for treating cancers